Tau-related grey matter network breakdown across the Alzheimer’s disease continuum
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Tau-related grey matter network breakdown across the Alzheimer’s disease continuum ; volume:13 ; number:1 ; day:13 ; month:8 ; year:2021 ; pages:1-11 ; date:12.2021
Alzheimer's research & therapy ; 13, Heft 1 (13.8.2021), 1-11, 12.2021
- Urheber
-
Pelkmans, Wiesje
Ossenkoppele, Rik
Dicks, Ellen
Strandberg, Olof
Barkhof, Frederik
Tijms, Betty M.
Pereira, Joana B.
Hansson, Oskar
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13195-021-00876-7
- URN
-
urn:nbn:de:101:1-2021110221311231273884
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pelkmans, Wiesje
- Ossenkoppele, Rik
- Dicks, Ellen
- Strandberg, Olof
- Barkhof, Frederik
- Tijms, Betty M.
- Pereira, Joana B.
- Hansson, Oskar
- SpringerLink (Online service)
Ähnliche Objekte (12)
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Fluid biomarkers in Alzheimer’s disease – current concepts
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
Blood‐based biomarkers for Alzheimer's disease
[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Alpha-amylase 1A copy number variants and the association with memory performance and Alzheimer’s dementia
Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Fluid biomarkers in Alzheimer’s disease – current concepts
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
Blood‐based biomarkers for Alzheimer's disease
[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Alpha-amylase 1A copy number variants and the association with memory performance and Alzheimer’s dementia
Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Fluid biomarkers in Alzheimer’s disease – current concepts
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
Blood‐based biomarkers for Alzheimer's disease
[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Alpha-amylase 1A copy number variants and the association with memory performance and Alzheimer’s dementia